ForouzanfarMH,AlexanderL,AndersonHR,BachmanVF,BiryukovS,BrauerM,BurnettR, 2015.A systematic analysis for the Global Burden of Disease Study 2013,Lancet 386 2287 -323
LimSS,VosT,FlaxmanAD,DanaeiG,ShibuyaK,Adair-RohaniH, 2012.A systematic analysis for the Global Burden of Disease Study 2010,Lancet 380 2224 -60
SharmaR,KamalakarS,McCarthyE,FieldsTA,GuptaK,BaruaR, 2014.Proteinuria in Hypertensive Nephropathy: A Review,Open Journal of Nephrology 4 92 -99
MillsKT,BundyJD,KellyTN,ReedJE,KearneyPM,ReynoldsK, 2016.Global disparities of hypertension prevalence and control. A systematic analysis of population-based studies from 90 countries,Circulation 134 441 -50
AlleyneG,BinagwahoA,HainesA,JahanS,NugentR,RojhaniA, 2013.Embedding noncommunicable diseases in the post-2015 development agenda,Lancet 381 566 -74
ErbelR,AboyansV,BoileauC,BossoneE,BartolomeoRD,EggebrechtH, 2014.ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The task force for the diagnosis and treatment of aortic diseases of the european society of cardiology (ESC),Eur Heart J 35 2873 -926
JamesPA,OparilS,CarterBL,CushmanWC,DennisonHimmelfarbC,HandlerJ, 2014.-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8),JAMA 311 507 -20
KuyperLM,KhanNA, 2014.Atenolol vs non-atenolol β-Blockers for the treatment of hypertension: A Meta-analysis,Can J Cardiol 30 S47 -53
Cooper-DeHoffRM,BirdST,NicholsGA,DelaneyJA,WintersteinAG, .Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study,J Am Heart Assoc2013; 2 e000125 -
ChoiHK,SorianoLC,ZhangY,RodríguezLAG, 2012.Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study,BMJ 344 d8190 -
ManolisA,DoumasM., 2012.Antihypertensive treatment and sexual dysfunction,Curr Hypertens Rep 14 285 -92
MallatSG, 2012.What is a preferred angiotensin II receptor blockerbased combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?,Cardiovasc Diabetol 11 32 -
MichelMC,FosterC,BrunnerHR,Liu L, 2013.A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists,Pharmacol Rev 65 809 -48
StafylasPC,SarafidisPA, 2008.Carvedilol in hypertension treatment,Vasc Health Risk Manag 4 23 -30
PavlikVN,GreisingerAJ,PoolJ,HaidetP,HymanDJ, 2009.Does reducing physician uncertainty improve hypertension control? Rationale and methods,Circ Cardiovasc Qual Outcomes 2 257 -63
HisatoTakagi,TakuyaUmemoto, 2014.A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients,J Am Soc Hypertens 8 578 -92
ZhuDL,GaoPJ,LiuSW,JeongMH,MattheusM,BirgitV, 2013.Efficacy and tolerability of a single-pill combination of telmisartan/hydrochlorothiazide 80/25 mg in Chinese and Korean patients with moderate to severe hypertension: A subgroup analysis of a randomized, double-blind, activecontrolled trial,Chin Med J 126 4072 -77
FreytagF,SchellingA,MeinickeT., 2001.Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild-to-moderate hypertension: a randomized, multicenter study,Clin Ther 23 108 -23
AlcocerL,Fernández-BonettiP,CamposE,Olvera RuizR,BahenaJ,de la FuenteJJ, 2004.Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension,Int J Clin Pract Suppl 58 35 -39